Importantly, the increased MHC-I surface expression by PIKfyve inhibition was also observed in various human cancer models, including MIA PaCa2, LNCaP, and prostate cancer patient–derived xenografts (SI Appendix, Fig. S1 B–D). This evidence concerns the gene PIKFYVE and Familial prostate cancer.